Takeda antes up $44M for rare disease pact, turning to Oxford spinout's exosome tech
More than two weeks into Takeda’s new work guidelines in response to the Covid-19 crisis — ordering staffers to work from home and stay off …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
